NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $2.70 -0.05 (-1.82%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$2.70 0.00 (0.00%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CytomX Therapeutics Stock (NASDAQ:CTMX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CytomX Therapeutics alerts:Sign Up Key Stats Today's Range$2.66▼$2.7850-Day Range$2.69▼$3.7252-Week Range$2.66▼$8.21Volume3.03 million shsAverage Volume4.28 million shsMarket Capitalization$588.33 millionP/E RatioN/ADividend YieldN/APrice Target$11.90Consensus RatingModerate Buy Company Overview CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company focused on developing cancer therapies designed to selectively activate in the tumor microenvironment. The company’s Probody therapeutic platform uses molecular masking technology intended to limit antibody activity in healthy tissue and enable activation by proteases that are more prevalent in tumors. CytomX’s pipeline includes investigational therapies spanning several modalities, including Probody drug conjugates, T-cell engagers and cytokine-based treatments. Its programs have included CX-2051, a CEACAM5-directed Probody drug conjugate; CX-904, a conditionally active T-cell engager targeting EGFR; and CX-801, an investigational tumor-targeted interferon-based therapy. These candidates are being studied for potential use in solid tumors, although the company does not currently market an approved product. Founded in 2008 and headquartered in South San Francisco, California, CytomX has advanced its programs through internal research and collaborations with pharmaceutical companies, including Astellas Pharma and Bristol Myers Squibb. The company’s therapies are intended for development and potential commercialization in international oncology markets, subject to clinical and regulatory approval. CytomX has been led by President and Chief Executive Officer Sean McCarthy, Ph.D., a co-founder of the company.AI Generated. May Contain Errors. Read More CytomX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCTMX MarketRank™: CytomX Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 624th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingCytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCytomX Therapeutics has a consensus price target of $11.90, representing about 340.7% upside from its current price of $2.70.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about CytomX Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytomX Therapeutics has a P/B Ratio of 4.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CytomX Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.43% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 9.29.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 15.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.65 News SentimentCytomX Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CytomX Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for CTMX on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.80% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTMX Stock News HeadlinesComparing IDEAYA Biosciences (NASDAQ:IDYA) and CytomX Therapeutics (NASDAQ:CTMX)1 hour ago | americanbankingnews.comCytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - SlideshowSeptember 10, 2026 | seekingalpha.comCytomX Therapeutics to Present at Upcoming September Investor ConferencesSeptember 1, 2026 | globenewswire.comCytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)August 27, 2026 | globenewswire.comCytomX Therapeutics: Promising Varseta-M With Comfortable RunwayAugust 12, 2026 | seekingalpha.comCytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comSee More Headlines CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $4.26 at the start of the year. Since then, CTMX stock has decreased by 36.6% and is now trading at $2.70. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. The biotechnology company had revenue of $1.42 million for the quarter, compared to the consensus estimate of $12.39 million. CytomX Therapeutics had a negative net margin of 435.21% and a negative trailing twelve-month return on equity of 38.46%. Read the conference call transcript. When did CytomX Therapeutics IPO? CytomX Therapeutics (CTMX) raised $100 million in an initial public offering (IPO) on Thursday, October 8th 2015. The company issued 6,666,667 shares at $14.00-$16.00 per share. Who are CytomX Therapeutics' major shareholders? Top institutional investors of CytomX Therapeutics include BlackRock Inc. (10.32%), Bank of America Corp DE (6.92%), Wellington Management Group LLP (2.37%) and Elmind Capital LP (2.09%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Christopher Ogden, Yu-Waye Chu, Lloyd A Rowland and Jeffrey B Landau. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/06/2026Today9/27/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CTMX's financial health is in the Yellow zone, according to TradeSmith. CTMX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CTMX CIK1501989 Webwww.cytomx.com Phone(650) 515-3185Fax650-351-0353Employees69Year Founded2008Price Target and Rating Average Price Target for CytomX Therapeutics$11.90 High Price Target$16.00 Low Price Target$6.00 Potential Upside/Downside+340.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.37 million Net Margins-435.21% Pretax Margin-433.95% Return on Equity-38.46% Return on Assets-30.33% Debt Debt-to-Equity RatioN/A Current Ratio9.36 Quick Ratio9.36 Sales & Book Value Annual Sales$76.20 million Price / Sales7.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book4.66Miscellaneous Outstanding Shares217,900,000Free Float209,619,000Market Cap$588.33 million OptionableOptionable Beta2.14 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CTMX) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
